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Abstract
Background: Attention deficit hyperactivity disorder (ADHD) is the most common neurological
condition in children. This pilot study evaluated the effects of high-dose eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) supplementation on the isolated plasma phospholipids and
behavior in children with ADHD (primarily inattentive subtype and combined subtype).
Methods: Nine children were initially supplemented with 16.2 g EPA/DHA concentrates per day.
The dosage was adjusted dependent on the ratio of arachidonic acid (AA) to EPA in the isolated
plasma phospholipids at four weeks to reach a level normally found in the Japanese population.
Results: At the end of the eight-week study, supplementation resulted in significant increases in
EPA and DHA, as well as a significant reduction in the AA:EPA ratio (20.78 ± 5.26 to 5.95 ± 7.35,
p < 0.01). A psychiatrist (blind to supplement compliance or dosage modifications) reported
significant improvements in behavior (inattention, hyperactivity, oppositional/defiant behavior, and
conduct disorder). There was also a significant correlation between the reduction in the AA:EPA
ratio and global severity of illness scores.
Conclusion: The findings of this small pilot study suggest supplementation with high-dose EPA/
DHA concentrates may improve behavior in children with ADHD.
Background
Attention deficit hyperactivity disorder (ADHD) is a neu-
rological condition characterized by the inability to con-
centrate in a sustained manner, to pay attention to tasks,
and to control impulsive actions [1]. It is estimated that 3
to 7 percent of children have this disorder, and boys are
affected to a much greater extent than girls [2]. As many as
60 to 80 percent of children with ADHD continue to have
problems with this condition as they become adults [1].
The etiology appears to be multi-factorial with both
genetic and environmental influences. Among these influ-
ences is an observed decrease in long-chain (LC) polyun-
saturated fatty acids (PUFAs) in children with ADHD.
Some proposed mechanisms for the low levels of PUFAs
include insufficient dietary intake, inefficient conversion
of shorter chain PUFAs to LC PUFAs or rapid metabolism
of LC PUFAs [3]. Stevens et al. [4,5] found that young boys
with ADHD and symptoms of essential fatty acid (EFA)
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deficiency (excessive thirst, dry skin and hair, brittle nails,
frequent urination and/or hyperfollicular keratoses) are
characterized by low levels of LC PUFAs, including AA,
EPA and DHA in the plasma phospholipids compared to
control. This group of children with ADHD also had a
high ratio of AA to EPA compared to control (68.87 vs.
45.83 respectively) suggesting the depression of EPA was
greater than that of AA [4,5]. Other studies from the same
group have also reported greater AA:EPA ratios in children
[3] and young adults [6] with ADHD compared to con-
trol.
The findings that children with ADHD have altered PUFA
levels led to interventional studies that supplemented
with these fatty acids. Hirayama et al. [7] found that sup-
plementation of 0.61 g of LC omega-3 fatty acids per day
for two months (primarily DHA in foods) had no effect
when analyzing parent and teacher assessments separately
in children with ADHD; however, when analyzing assess-
ments together, physical aggression significantly
improved compared to the placebo group [8]. Voigt et al.
[9] supplemented children with ADHD for four months
with 0.35 g of DHA per day and found no improvements
in any ADHD symptoms. Richardson and Puri [10] sup-
plemented children with ADHD related symptoms, pri-
marily dyslexia, for three months with 1.67 g per day of
omega-3 and omega-6 fatty acids or olive oil placebo in a
double-blind randomized fashion. Half of the scales
tested (seven of 14) improved compared to placebo,
including cognition, anxiety/shyness, psychosomatic sub-
scales, restlessness/impulsivity and three global scales;
however, the participants were children with ADHD-
related symptoms not diagnosed with ADHD in accord-
ance to DSM IV criteria. The only study that measured the
AA:EPA ratio was that of Stevens et al. [11] who supple-
mented children with ADHD and symptoms of EFA defi-
ciency with 0.66 g per day of both omega-3 and omega-6
PUFAs for four months. Although the AA:EPA ratio
decreased from 33.04 to 15.19, only two of 16 behavioral
outcome measures significantly improved compared to
the placebo group suggesting the decreased AA:EPA ratio
may not have been lowered enough to observe a greater
impact on behavior.
Depression is often a co-morbidity of ADHD and an
increased AA:EPA ratio has been shown to positively cor-
relate with severity of depression [12]. High-dose dietary
supplementation with EPA and DHA (9.6 g) has been
shown as an effective adjunctive treatment for bipolar
depression [13]. Epidemiological data has shown that the
Japanese population has low rates of depression [14],
compared to the US population and they have a high
intake of fish and low AA:EPA ratio [15]. The ratio of
AA:EPA in the isolated plasma phospholipids of the Japa-
nese population is approximately 1.3 to 3 [15,16]; young
boys with ADHD in the United States had AA:EPA ratios
greater than 30 [4,5,11]. A recent study found negative
correlations between omega-3 status and behavior in
young adults with ADHD suggesting lower omega-3 status
may be associated with severity of behavioral symptoms
[6].
The interventional studies in children with ADHD dem-
onstrate that some behavior may improve with PUFA sup-
plementation [5,8,10]; however, the findings have not
been consistent and few have monitored fatty acid levels
in the plasma phospholipids. A possible association
between ADHD behaviors and omega-3 status, particu-
larly the AA:EPA ratio and the lack of consistent results led
us to hypothesize that insufficient levels of omega-3 fatty
acids, or lack of sufficient reduction of the AA:EPA ratio,
are two possible explanations for the inconsistent findings
of previous studies. To address this hypothesis, we under-
took an open-label pilot study to first determine if chil-
dren with ADHD would adhere to a protocol of high-dose
EPA/DHA concentrates (initial dosage of 16.2 g EPA and
DHA per day) to reach the goal AA:EPA ratio between 1.5
and 3 as found in the Japanese population. Second,
behavior was assessed by a psychiatrist specialized in this
childhood disorder to measure what effect such a reduced
AA:EPA ratio would have on behavior.
Methods
Study design and participants
This was an eight-week, open-label, proof-of-efficacy pilot
study. Nine children aged 8–16 were recruited from the
patient population under treatment for ADHD-primarily
inattentive subtype or ADHD-combined subtype at the
Hallowell Center, Sudbury, MA. There were more boys (n
= 6) than girls (n = 3). Two-thirds (n = 6) presented with
ADHD-combined subtype, and one-third (n = 3) with
ADHD-primarily inattentive subtype according to criteria
of the Diagnostic Statistical Manual (DSM) IV [17]. Two
of the three participants who presented with ADHD-pri-
marily inattentive subtype were girls. Participant charac-
teristics are outlined in Table 1. All participants had an
established relationship with the psychiatrist involved in
the study. Three participants voluntarily discontinued
stimulant medication prior to study initiation with the
psychiatrist's approval. The remainder continued with
their treatment regime for the duration of the study. There
were no medication dosage changes during the course of
the eight-week study. Children and parents/guardians
provided informed and written assent and consent respec-
tively. Integreview, Houston, TX, approved the study for
the use of human subjects in research.
Study intervention
At the start of the study, all participants were instructed to
consume two tablespoons (30 mL) of a liquid EPA/DHANutrition Journal 2007, 6:16 http://www.nutritionj.com/content/6/1/16
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concentrate (supplied by the Inflammation Research
Foundation) providing 16.2 g of LC omega-3 fatty acids
(10.8 g EPA and 5.4 g DHA) per day. The EPA/DHA con-
centrate dosage was adjusted at week four based on the
AA:EPA ratio in the isolated plasma phospholipids as fol-
lows: if the AA:EPA ratio was below 1.0, the dosage was
decreased to 15 ml (5.4 g EPA, 2.7 g DHA per day), if the
AA:EPA ratio was between 1.0 and 1.5 the dosage was
decreased to 20 ml (8.1 g EPA, 4 g DHA per day). Isolated
plasma phospholipids are not subject to daily fluctuations
in dietary intake and are a reliable marker of fatty acid lev-
els [18] and correlate to dietary intake of fatty fish [19-21]
and fish oil supplementation [22,23]. EPA levels were
used to monitor adherence to the supplementation proto-
col and the participant's parent/guardian was phoned
once per week to monitor adherence and adverse effects of
the EPA/DHA concentrates. The children and at least one
parent/guardian met with the psychiatrist at three time
points: baseline (week 0), midpoint (week four) and con-
clusion (week eight). At the initial (baseline) visit partici-
pants were advised to follow a "healthy diet" that
encouraged fruits, vegetables and balanced intake of
macronutrients at meals and snacks. At each of the three
meetings, the psychiatrist conducted behavioral assess-
ments, and a phlebotomist drew blood for fatty acid anal-
ysis. Fatty acid analysis of the isolated plasma
phospholipids was completed by Nutrasource Diagnos-
tics, Guelph, ON, Canada, as described by Laidlaw and
Holub [23].
Behavioral assessment
The ADHD Symptom Checklist-4 (ADHD SC-4) was used
to monitor behavioral changes by the psychiatrist at each
meeting. Retrospectively the psychiatrist asked the parent/
guardian and child each of the checklist questions and
also observed symptoms during the process. This ques-
tionnaire categorizes behavior as inattention, hyperactiv-
ity, oppositional/defiant, and conduct disorder. There was
also a section to monitor medication side effects. Inatten-
tion and hyperactivity scores can range from 0 to 27 each.
Oppositional/defiant scores range from 0 to 24 and con-
duct disorder from 0 to 3 [24,25].
The Clinical Global Impression Scale was used by the psy-
chiatrist to rate participants' severity of illness [26]. The
scores are derived from a 7-point Likert scale [26]. Severity
of illness ranged from 1 as normal (not at all sympto-
matic), to 7 as among the most symptomatic patients.
Although the psychiatrist knew the children were part of a
study, he was blind to dosage adjustments and protocol
adherence. The parents also completed the short form
Conner's Parent's Rating Scale (CPRS) [27-29] at baseline,
week four and week eight. Responses were scored and cat-
egorized into 4 groups: oppositional behavior, cognitive
problems/inattention, hyperactivity and an ADHD index.
Statistical analysis
Summary statistics are reported as mean ± SD and medi-
ans. Statistical analyses were performed using Stata for
Mac (version 9, StataCorp LP, College Station, Texas).
Fatty acids, ADHD SC-4, CPRS, and severity of illness were
reported for baseline (week 0), midpoint (week four) and
at the conclusion of the study (week eight). The non-par-
ametric Friedman test was used to assess changes over
time. If the Friedman test was statistically significant at the
0.05 level, then the Wilcoxon signed rank test was used as
a post-hoc test to compare changes from baseline to four
and eight weeks. Spearman correlations were used to
identify a relationship between changes in the primary
fatty acid outcome variable, the AA:EPA ratio, and the pri-
mary behavioral outcome variable, severity of illness.
Results
Effect of EPA/DHA concentrates on isolated plasma 
phospholipid fatty acid levels
Blood was monitored throughout the study to ensure that
the AA:EPA ratio was greater than 1.0 because of the
potential concern with high-dose EPA/DHA supplemen-
tation on prolonged bleeding times; although, a recent
study of the Japanese indicated no adverse effects related
to EPA intake in patients whose AA:EPA ration was low-
ered to 0.8 [15]. To maintain the goal AA:EPA ratio
between 1.5 and 3 dosage adjustments were made at week
four based on fatty acid results. At week four, three partic-
ipants had an AA:EPA ratio below 1.0 and adjusted their
EPA/DHA concentrate dosage to 15 ml per day; two par-
ticipants had AA:EPA ratios between 1.0 and 1.5 and
adjusted their dosage to 20 ml EPA/DHA concentrate; the
remaining four participants had an AA:EPA ratio of 1.5 or
above, and were instructed to continue with the initial
daily dosage. Four of the five participants whose dosage
was adjusted at week four increased their AA:EPA ratio by
week eight, however the AA:EPA ratio remained less than
3 (Figure 1). Two participants had an AA:EPA ratio less
than one at week eight and upon exiting the study were
Table 1: Baseline Characteristics of Study Participants*
Age (y) 11.44 ± 1.51
Gender (% male) 67
Race (% white) 100
School grade 6.00 ± 1.77
ADD % 33
ADHD % 67
Years since diagnosis 2.63 ± 1.41
Height (in) 61.67 ± 5.13
Weight (lbs) 113.67 ± 34.04
Taking stimulant
medication (%) 67
* Reported values are means ± SD (n = 9) or percentages.Nutrition Journal 2007, 6:16 http://www.nutritionj.com/content/6/1/16
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advised to decrease the supplement dosage if they were to
continue with the protocol post study.
Overall, at the conclusion of the eight weeks of supple-
mentation, the average EPA and DHA levels in the isolated
plasma phospholipids significantly increased by a factor
of 9.5 and 2.4 respectively (Table 2). The AA tended to
decrease at eight weeks, although the reduction was not
significant (p = 0.07). As a consequence of AA and EPA
changes, there was a 71% reduction in the mean AA:EPA
ratio (20.78 ± 5.26 to 5.95 ± 7.35, p < 0.01) from baseline
to week eight. The EPA/DHA concentrate dosage adjust-
ment at week four resulted in the average EPA and DHA
levels to increase from week four to eight with a corre-
sponding 42% relative increase (4.19 ± .5.45 to 5.95 ±
7.35, p = 0.07) in the AA:EPA ratio; in contrast, the relative
increase in median AA:EPA ratio over the same period was
only 16% and better reflects the actual changes among
compliant study participants. Nonetheless, these increases
demonstrate sensitivity to EPA and DHA supplementa-
tion dosage.
Protocol adherence
The largest AA:EPA reduction for most participants
occurred in the first four weeks (Figure 2). Figure 2 shows
that one participant's AA:EPA ratio returned to baseline
levels at week eight following a reduction at week four.
Furthermore, this participant's EPA and DHA levels also
returned to near baseline levels, indicating poor compli-
ance from week four to eight. This participant's parent
reported poor protocol adherence for the second half of
the study, which mimics the fatty acid data. A second par-
ticipant who refused to consume the liquid was switched
to a capsule supplementation and was instructed to con-
sume 24 one-gram capsules (9.6 g EPA and 4.8 g DHA)
per day from week two to week eight. The lack of change
in the AA:EPA ratio in this participant indicated non-com-
pliance. We chose less than 100% increase in the isolated
plasma phospholipids for EPA and DHA as an indicator of
poor compliance. The two non-compliant children were
not of the same ADHD subtype or gender. All other par-
ticipants had greater than a 100% increase in both EPA
and DHA levels at the conclusion of the study and were
considered compliant with study supplementation proto-
col.
Adverse effects
One participant reported loose stools while taking 30 ml
of the liquid EPA/DHA concentrate per day. At week four,
the dosage was decreased to 15 ml per day with no subse-
quent adverse events. No observational effects on bleed-
ing were reported by the parents. One child had adverse
effects (tics) related to stimulant medication prior to study
Table 2: Fatty acids from the isolated plasma phospholipids 
described as means ± SD and median.*
Plasma FA Baseline Week 4 Week 8
n-6
18:2 (LA) 22.61 ± 1.39 17.81 ± 2.85 21.88 ± 4.89
median 21.95 17.49 21.08
20:3 (DGLA) 3.12 ± 0.44 1.86 ± 0.82 2.15 ± 0.64
median 3.09 2.25 2.05
20:4 (AA) 9.52 ± 0.70 8.92 ± 0.83 8.69 ± 1.30
median 9.34 8.92 8.37
n-3
18:3 (LNA) 0.13 ± 0.07 0.13 ± 0.07 0.13 ± 0.06
median 0.13 0.1 0.12
20:5 (EPA) 0.49 ± 0.12 5.89 ± 4.27a 4.64 ± 3.65a
median 0.46 6.13 4.72
22:6 (DHA) 2.30 ± 0.88 5.68 ± 1.28a 5.61 ± 2.14a
median 2.07 6.11 6.19
Totals and ratios
Saturated 44.29 ± 0.99 43.94 ± 1.26 42.19 ± 1.05
median 44.2 44.04 42.53
Monounsaturated 15.43 ± 1.38 13.64 ± 1.18 12.31 ± 2.12
median 15.7 13.51 11.93
Polyunsaturated 40.27 ± 1.03 42.41 ± 1.43 45.51 ± 1.26
median 40.21 42.02 45.38
total n-6 36.37 ± 0.99 29.07 ± 4.31a 33.42 ± 5.67
median 36.57 29.54 31.59
total n-3 3.90 ± 0.87 13.35 ± 5.27a 12.09 ± 6.17a
median 3.66 12.74 13.38
n-6: n-3 ratio 9.74 ± 2.14 2.79 ± 1.88a 3.93 ± 2.73a
median 9.61 2.39 2.36
AA:EPA ratio 20.78 ± 5.26 4.19 ± 5.45a 5.95 ± 7.35a
median 20.14 1.46 1.69
AA:EPA ratio 
(n = 7)#
20.73 ± 5.26 2.53 ± 3.49a 2.52 ± 2.91
median 19.58 1.34 1.39
* Values are mean ± SD and medians (n = 9). a p < 0.01 using 
Wilcoxon signed rank test to compare to baseline. LA, linoleic acid; 
DGLA, dihomogammalinolenic acid; AA, arachidonic acid; LNA, 
linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic 
acid.
AA:EPA ratio changes from week 4 to 8 in the participants  with EPA/DHA concentrate dosage changes.* Figure 1
AA:EPA ratio changes from week 4 to 8 in the partic-
ipants with EPA/DHA concentrate dosage changes.* 
* Each line represents a participant's AA:EPA ratio from 
week 4 to week 8 in the five who were instructed to 
decrease their intake of the EPA/DHA concentrate.Nutrition Journal 2007, 6:16 http://www.nutritionj.com/content/6/1/16
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initiation that continued throughout the study. Sleep dis-
turbance is another know adverse effect of medication for
the treatment for ADHD [30]; four of the nine children
had improvements in sleep noted by the parents.
Behavioral analysis
All categories of the ADHD SC-4 significantly improved
by week eight. Specifically, inattention, hyperactivity,
oppositional/defiant behavior and conduct disorder all
significantly improved over the course of the study (Table
3). The CPRS showed significant improvements (p < 0.05)
in all four categories (oppositional behavior, cognitive
problems/inattention, hyperactivity, and the ADHD
index) over the eight week study as well (Table 3). The
severity of illness score, assessed by the psychiatrist,
tended to improve (p = 0.08) over time. On average, the
severity of illness score decreased by 1 point from 4.4
(moderately symptomatic) to 3.3 (mildly symptomatic).
The two subjects who were identified as non-compliant
from parental reports and fatty acid levels were the only
participants who were scored a 5 (markedly symptomatic)
at baseline and week eight.
Correlations
There was a significant positive correlation of the percent
change in AA:EPA ratio with the percent change in severity
of illness (Rho = 0.7638, p = 0.027). However, the AA:EPA
ratio did not significantly correlate with the ADHD SC-4
or CPRS categories.
Discussion
Supplementation with high-dose EPA/DHA concentrate
resulted in significant modifications of fatty acids, partic-
ularly a significant improvement in the AA:EPA ratio in
the isolated plasma phospholipids and improvements in
behavior assessed by a psychiatrist (blinded to protocol
adherence and supplement dosage adjustments) in this
small pilot sample of children with ADHD.
At baseline fatty acid analysis of the isolated plasma phos-
pholipids from the children in this study were similar to
that of previous studies of children with ADHD and thirst/
Table 3: Behavioral assessment*
Assessment Baseline Week 4 Week 8
ADHD SC-4 Inattention 18.11 ± 5.37 10.56 ± 5.46a 9.78 ± 6.91a
median 17 9 10
ADHD SC-4 Hyperactivity 11.33 ± 4.53 7.67 ± 5.96 5.22 ± 3.99a
median 10 6 4
ADHD SC-4 Oppositional/defiant 10.11 ± 6.79 5.44 ± 3.88b 5.22 ± 3.56b
median 11 7 5
ADHD SC-4 Conduct disorder 5.22 ± 6.26 0.89 ± 0.93b 1.11 ± 2.26b
median 4 1 0
CPRS-Oppositional behavior 8.67 ± 4.58 5.38 ± 3.11 4.89 ± 2.93a
median 7 5.5 6
CPRS- Cognitive problems/inattention 11.56 ± 5.13 7.00 ± 3.89b 8.44 ± 6.48
median 12 8.5 8
CPRS- Hyperactivity 5.89 ± 3.79 2.63 ± 2.39 3.22 ± 4.49
median 6 3 2
CPRS- ADHD index 22.67 ± 9.03 13.63 ± 6.37a 15.44 ± 9.49b
median 22 13 14
Clinical Severity of Illness 4.38 ± 0.74 3.56 ± 0.73 3.33 ± 1.12c
median 4.5 3 3
* Values are mean ± SD and medians (n = 9). ADHD SC-4, Attention Deficit Hyperactivity Disorder Symptom Checklist 4. CPRS, Conners' Parents 
Rating Scale a p < 0.01, b p < 0.05 using Wilcoxon signed rank test to compare to baseline; c p = 0.08 using Friedman test to compare to baseline.
AA:EPA ratio changes at week 0, week 4 and week 8. * Figure 2
AA:EPA ratio changes at week 0, week 4 and week 
8.* *Each line represents a participant's AA:EPA ratio from 
baseline to week 4 and week 8, dashed lines represent the 
participants whose EPA/DHA concentrate dosage was not 
changed at week 4.Nutrition Journal 2007, 6:16 http://www.nutritionj.com/content/6/1/16
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skin symptoms of EFA deficiency [3,5,11]; however, we
did not assess EFA deficiency symptoms. Children with
ADHD and thirst/skin symptoms of EFA deficiency had
lower AA and DHA levels in the plasma phospholipids
compared to control groups. Both the AA and DHA mean
levels from previous studies [3,5,11] were within the 95%
CI (8.98–10.05; 1.63–2.97, respectively) of this study's
mean AA and DHA levels.
Supplementation of high-dose EPA/DHA concentrates
resulted in marked changes in fatty acid levels of the iso-
lated plasma phospholipids. EPA and DHA levels in the
isolated plasma phospholipids were used to monitor
compliance. We chose the AA:EPA ratio as an important
marker because of it's relationship with depression [12],
as depression is often associated with ADHD [31]. In this
study, there was indeed a significant positive correlation
between the AA:EPA ratio and severity of illness.
Although the EPA and DHA supplementation dosages
used in this study were high compared to previous studies
with children, there was no serious adverse effect except
one case of loose stools that was corrected with a lower
dose. Young et al. [32] supplemented adults with ADHD
with high-dose EPA/DHA concentrates (approximately 36
g EPA and DHA per day) with no reported serious adverse
effects other than loose stools and fishy burps. The aver-
age AA:EPA ratio after 12 weeks of the high-dose EPA/
DHA supplementation in adults with ADHD was 1.4 ± 0.6
[32]; however, behavior was not assessed in this study.
Stevens et al. [11] supplemented children with ADHD and
thirst/skin symptoms with 480 mg DHA, 80 mg EPA, 40
mg AA and 60 mg GLA per day. At these levels, the AA:EPA
ratio was reduced to15.19 after four months [11], which
remains 2.5 times greater than the mean AA:EPA ratio
obtained in this study. Stevens et al. [11] did monitor
behavior and found improvements in conduct assessed by
the parents and attention assessed by the teachers in the
PUFA group compared to olive oil placebo. When
assessed clinically, the parental rating scales were also
evaluated based on diagnostic criteria, and a significant
PUFA treatment effect was reported for oppositional/defi-
ant disorder. The findings by Stevens et al. [11] supports
our data in that we also found improvements in opposi-
tional behaviors rated by the parents and improvements
in both oppositional/defiant behaviors and conduct
assessed clinically by the psychiatrist, however, a psychia-
trist did not assess behavior in Stevens et al.'s study.
This study found a statistically significant improvement in
the psychiatrist's report of inattention, hyperactivity,
oppositional/defiant behavior and conduct disorder
based on the ADHD SC-4 questionnaire. Scores for inat-
tention, hyperactivity and oppositional/defiant behavior
continued to improve from week four to eight, even with
the EPA/DHA concentrate dosage adjustment. The dosage
adjustment, however, did not bring the AA:EPA ratio
above 3 suggesting the importance of monitoring fatty
acids and the AA:EPA ratio in particular rather than EPA/
DHA dosage alone. The severity of illness scale demon-
strated a positive improvement from an average of mod-
erately symptomatic to mildly symptomatic. This
improvement was similar regardless of medication use or
lack there of. The percent change in severity of illness also
correlated with percent decrease in the AA:EPA ratio, sug-
gesting a connection between the clinical improvement
observed by the psychiatrist and the improvements in the
AA:EPA ratio.
Data from Stevens et al. [11] in children and Young et al.
[32] in adults with ADHD suggest that greater amounts of
both EPA and DHA may be required to decrease the
AA:EPA ratio to between 1.5 and 3. The mean AA:EPA
ratio at the end of this study was 5.95 ± 7.35 for all partic-
ipants. When the two participants who were non-compli-
ant were removed, the AA:EPA ratio was 2.52 ± 2.91,
suggesting a daily dose between 8.1 g and 16.2 g of EPA/
DHA concentrate may be appropriate to decrease the
AA:EPA ratio to between 1.5 and 3 and to observe
improvements in behavior in children with ADHD.
There are a number of limitations to this pilot study and
therefore interpretation of results requires caution. The
study is limited in that there was no placebo group for ref-
erence comparisons as this was a pilot study to determine
appropriate dosage for protocol adherence and to main-
tain AA:EPA levels between 1.5 and 3. Dietary intake was
not recorded at baseline or monitored throughout the
study; therefore, we are unable to decipher intake of fatty
acids from the diet. Also related to diet, we advised the
children to eat more fruits and vegetables and consume
meals and snacks that are balanced with protein, carbohy-
drates (preferably fruit and vegetables) and "healthy"
monounsaturated fats. Advice for following both a
"healthy diet" and high-dose fish oil supplementation
may have been confounding factors. However, the dose-
response relationship between percent change in AA:EPA
ratio and the reduction in the severity of ADHD suggest
the behavioral changes were due to, at least in part, the
intake of high-dose EPA/DHA concentrates. The lack of
behavioral change or regression to pre-study status in
those subjects who were least compliant to supplementa-
tion also suggest that behavioral changes were associated
with intake of the LC omega-3 fatty acids.
EPA/DHA concentrate dosage adjustments themselves
can be viewed as a limitation since some, but not all par-
ticipants' daily intake dosage was modified at week four.
The supplement intervention adjustment was based onNutrition Journal 2007, 6:16 http://www.nutritionj.com/content/6/1/16
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the AA:EPA ratio, therefore those whose AA:EPA ratio
dropped below the goal range was adjusted upward and
by using this ratio as our goal, we also avoided most
adverse events. The lack of a proper means to monitor
supplement intake, such as weight of returned bottles, was
also a limitation of this study. However, this was compen-
sated for by use of isolated plasma phospholipids levels as
a means to monitor protocol adherence.
Conclusion
Although this was a small one-arm study, the results are
encouraging as they suggest that high-dose EPA and DHA
(up to 16.2 g per day) can be given to children with good
adherence. Also, our results concur with trends and signif-
icant findings of some, but not all studies of PUFA supple-
mentation in children with ADHD or related symptoms
[8,10,11]. The inconsistent findings from previous studies
and our results suggest that greater dosages of EPA are
needed to decrease the AA:EPA ratio to levels similar to
the Japanese population and to observe significant behav-
ioral improvements. The findings of this study suggest
that children with ADHD and a high AA:EPA ratio might
be responsive to treatment with EPA and DHA supple-
mentation to bring the AA:EPA ratio to below 3.
The preliminary results found in this pilot study warrant
future randomized, placebo-controlled, double blind
studies that use participant's AA:EPA ratios to determine
EPA/DHA supplementation dosage for adjunct treatment
of ADHD in children.
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